Business history is also littered with companies a
Post# of 148288
Monoclonal antibodies have and continue to upend the pharmaceutical industry.
Very few of us doubt that Cytodyn needs to partner to reach scale post-approval.
IMO, it will not be quick or easy for others to develop a better CCR5 receptor antibody until leronlimab patent expiration.
This be provide quite a moat for Cytodyn. Time will tell.
Invest according to your beliefs. I have.